0001628280-26-033135
SEC filingBicara Therapeutics reported Q1 2026 net loss of $56.2 million, cash position of $539.8 million funding into 1H 2029, clinical progress in ficerafusp alfa trials, and key executive changes.
Bicara Therapeutics' Q1 2026 results reflect accelerated investment in its lead asset ficerafusp alfa, with R&D expenses rising 38% year-over-year to $47.5 million primarily from FORTIFI-HN01 pivotal trial costs, Phase 1b expansions, and headcount growth. G&A increased 69% to $12.7 million due to personnel and professional fees supporting clinical advancement, driving a net loss of $56.2 million or $(0.93) per share versus $36.8 million or $(0.68) in Q1 2025. Cash position strengthened significantly to $539.8 million after $161.8 million net proceeds from an oversubscribed public offering, extending runway into first half of 2029 and de-risking operations through key milestones. Clinical momentum includes strong FORTIFI-HN01 execution targeting substantial enrollment by year-end for mid-2027 interim analysis toward accelerated approval in 1L R/M HPV-negative HNSCC, plus a new Q3 2026 randomized study of optimized loading/Q3W dosing with pembrolizumab based on FDA discussions. Long-term Phase 1b data at ASCO 2026 (May 29-June 2) will highlight TGF-β's role in response durability. Executive shifts position the company for commercialization: Bill Schelman's promotion to CMO brings clinical expertise, David Raben's advisory role retains strategic insight, and Chris Sarchi's CCO appointment leverages oncology launch experience.